vs
Amarin Corp plc（AMRN）与HERITAGE COMMERCE CORP（HTBK）财务数据对比。点击上方公司名可切换其他公司
HERITAGE COMMERCE CORP的季度营收约是Amarin Corp plc的1.2倍（$53.6M vs $45.1M），HERITAGE COMMERCE CORP净利率更高（28.2% vs -23.3%，领先51.5%），HERITAGE COMMERCE CORP同比增速更快（15.6% vs 7.0%），过去两年HERITAGE COMMERCE CORP的营收复合增速更高（12.8% vs -18.3%）
Amarin是一家1993年成立的爱裔美籍生物制药企业，总部分别设于爱尔兰都柏林与美国新泽西州布里奇沃特。该企业专注研发及销售心血管疾病治疗药物，已推出处方级Omega-3脂肪酸药物Vascepa（AMR-101）。
本文介绍的企业主体信息与内容描述不符，描述内容实际为美国商会，该商会成立于1912年4月23日，是美国规模最大的游说类商业协会 advocacy 团体，成立之初得益于时任总统威廉·霍华德·塔夫脱与劳工商务部长查尔斯·内格尔推动，旨在代表工商界发声。
AMRN vs HTBK — 直观对比
营收规模更大
HTBK
是对方的1.2倍
$45.1M
营收增速更快
HTBK
高出8.6%
7.0%
净利率更高
HTBK
高出51.5%
-23.3%
两年增速更快
HTBK
近两年复合增速
-18.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $53.6M |
| 净利润 | $-10.5M | $15.1M |
| 毛利率 | — | — |
| 营业利润率 | 35.5% | 41.0% |
| 净利率 | -23.3% | 28.2% |
| 营收同比 | 7.0% | 15.6% |
| 净利润同比 | 33.0% | 42.3% |
| 每股收益（稀释后） | — | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRNHTBK
| Q1 26 | $45.1M | — | ||
| Q4 25 | $49.2M | $53.6M | ||
| Q3 25 | $49.7M | $50.0M | ||
| Q2 25 | $72.7M | $47.8M | ||
| Q1 25 | $42.0M | $46.1M | ||
| Q4 24 | $62.3M | $46.4M | ||
| Q3 24 | $42.3M | $42.2M | ||
| Q2 24 | $67.5M | $41.7M |
净利润AMRNHTBK
| Q1 26 | $-10.5M | — | ||
| Q4 25 | $-1.2M | $15.1M | ||
| Q3 25 | $-7.7M | $14.7M | ||
| Q2 25 | $-14.1M | $6.4M | ||
| Q1 25 | $-15.7M | $11.6M | ||
| Q4 24 | $-48.6M | $10.6M | ||
| Q3 24 | $-25.1M | $10.5M | ||
| Q2 24 | $1.5M | $9.2M |
毛利率AMRNHTBK
| Q1 26 | — | — | ||
| Q4 25 | 47.1% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 69.2% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | -15.4% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 63.4% | — |
营业利润率AMRNHTBK
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | 41.0% | ||
| Q3 25 | -22.4% | 41.1% | ||
| Q2 25 | -22.0% | 18.7% | ||
| Q1 25 | -39.9% | 35.4% | ||
| Q4 24 | -84.3% | 31.8% | ||
| Q3 24 | -59.5% | 34.3% | ||
| Q2 24 | -0.8% | 31.3% |
净利率AMRNHTBK
| Q1 26 | -23.3% | — | ||
| Q4 25 | -2.5% | 28.2% | ||
| Q3 25 | -15.6% | 29.4% | ||
| Q2 25 | -19.4% | 13.4% | ||
| Q1 25 | -37.4% | 25.2% | ||
| Q4 24 | -78.0% | 22.9% | ||
| Q3 24 | -59.4% | 24.9% | ||
| Q2 24 | 2.3% | 22.1% |
每股收益（稀释后）AMRNHTBK
| Q1 26 | — | — | ||
| Q4 25 | $0.00 | $0.25 | ||
| Q3 25 | $-0.02 | $0.24 | ||
| Q2 25 | $-0.03 | $0.10 | ||
| Q1 25 | $-0.04 | $0.19 | ||
| Q4 24 | $-0.12 | $0.17 | ||
| Q3 24 | $-0.06 | $0.17 | ||
| Q2 24 | $0.00 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $307.8M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $708.6M |
| 总资产 | $645.8M | $5.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRNHTBK
| Q1 26 | $307.8M | — | ||
| Q4 25 | $302.6M | — | ||
| Q3 25 | $286.6M | — | ||
| Q2 25 | $298.7M | — | ||
| Q1 25 | $281.8M | — | ||
| Q4 24 | $294.2M | — | ||
| Q3 24 | $305.7M | — | ||
| Q2 24 | $306.7M | — |
股东权益AMRNHTBK
| Q1 26 | — | — | ||
| Q4 25 | $459.3M | $708.6M | ||
| Q3 25 | $458.9M | $700.0M | ||
| Q2 25 | $464.9M | $694.7M | ||
| Q1 25 | $473.7M | $696.2M | ||
| Q4 24 | $486.2M | $689.7M | ||
| Q3 24 | $531.4M | $685.4M | ||
| Q2 24 | $551.9M | $679.2M |
总资产AMRNHTBK
| Q1 26 | $645.8M | — | ||
| Q4 25 | $670.8M | $5.8B | ||
| Q3 25 | $659.8M | $5.6B | ||
| Q2 25 | $670.1M | $5.5B | ||
| Q1 25 | $655.7M | $5.5B | ||
| Q4 24 | $685.3M | $5.6B | ||
| Q3 24 | $750.6M | $5.6B | ||
| Q2 24 | $799.9M | $5.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $61.7M |
| 自由现金流经营现金流 - 资本支出 | — | $61.3M |
| 自由现金流率自由现金流/营收 | — | 114.3% |
| 资本支出强度资本支出/营收 | — | 0.7% |
| 现金转化率经营现金流/净利润 | — | 4.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMRNHTBK
| Q1 26 | — | — | ||
| Q4 25 | $15.3M | $61.7M | ||
| Q3 25 | $-12.7M | $18.9M | ||
| Q2 25 | $16.6M | $8.0M | ||
| Q1 25 | $-12.5M | $14.8M | ||
| Q4 24 | $-13.3M | $39.0M | ||
| Q3 24 | $-2.4M | $5.3M | ||
| Q2 24 | $-2.7M | $10.5M |
自由现金流AMRNHTBK
| Q1 26 | — | — | ||
| Q4 25 | — | $61.3M | ||
| Q3 25 | — | $18.8M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $37.3M | ||
| Q3 24 | — | $4.9M | ||
| Q2 24 | — | $9.9M |
自由现金流率AMRNHTBK
| Q1 26 | — | — | ||
| Q4 25 | — | 114.3% | ||
| Q3 25 | — | 37.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 80.5% | ||
| Q3 24 | — | 11.6% | ||
| Q2 24 | — | 23.6% |
资本支出强度AMRNHTBK
| Q1 26 | — | — | ||
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 1.6% |
现金转化率AMRNHTBK
| Q1 26 | — | — | ||
| Q4 25 | — | 4.08× | ||
| Q3 25 | — | 1.28× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.28× | ||
| Q4 24 | — | 3.67× | ||
| Q3 24 | — | 0.50× | ||
| Q2 24 | -1.81× | 1.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
HTBK
暂无分部数据
